RT Journal Article
SR 00
ID 10.1080/13571516.2015.1122969
A1 Berndt, Ernst  R.
A1 Dubois, Pierre
T1 Impacts of Patent Expiry of Pharmaceutical Treatments in Eight OECD Countries, 2004-2010
JF International Journal of the Economics of Business
YR 2016
FD 2016-05
VO vol. 23
IS n° 2
SP 125
OP 147
K1 Cross-Country Comparisons
K1 Pharmaceutical Costs
K1 Generic Drugs
AB Variability in regulatory frameworks, industrial policy, physician/pharmacy autonomy, brand/generic distinctions, and the practice of medicine contribute to ambiguous interpretations of cross-country pharmaceutical cost comparisons. Here, we report cross-country comparisons that: (i) focus on ten therapeutic classes experiencing patent expiration and loss of exclusivity 2004–2010 in eight industrialized countries; (ii) convert revenues and unit sales to cost per day of treatment and number patient days treated using the World Health Organization’s Defined Daily Dosage metrics; (iii) compare patterns in costs per day of treatment with price index measures based on average price per day of treatment for each molecule computed over all molecule versions; (iv) utilizing econometric methods, model and quantify various factors affecting variations in daily treatment price indexes such as national regulatory and reimbursement policy changes, physician/pharmacy autonomy, and other factors; and (v) simulate changes in expenditures by country and therapeutic class had counterfactual policies been implemented.
PB Taylor & Francis
SN 1357-1516
LK https://publications.ut-capitole.fr/id/eprint/19381/
UL http://tse-fr.eu/pub/30081